The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia
Yunchao Chang(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital)
Cited by 37
Related Papers
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
JAK mutations in high-risk childhood acute lymphoblastic leukemia
|Proceedings of the National Academy of Sciences|2009|559
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia
|Nature Communications|2016|293
Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL
|JCI Insight|2016|59